Three-time Olympic gold medalist Kallie Humphries spent $70,000 on fertility treatments—more than triple her initial estimate. She underwent five IVF cycles and four embryo transfers before giving birth to her son, exhausting her family's resources and requiring financial help from a relative to continue.
Her experience reflects a broader financial squeeze facing American families pursuing fertility care. Only 32 percent of employer health plans cover fertility medications, according to the White House Council of Economic Advisers, forcing most families to pay out of pocket.
The Trump administration's TrumpRx program aims to ease that burden by negotiating lower cash prices for fertility drugs outside the traditional insurance system. The council estimates that medications for a standard IVF cycle have dropped from over $5,000 to approximately $3,000—a $2,000 reduction.
The largest savings come from Gonal-F, a primary ovarian stimulation drug. Its cost fell from about $3,000 to $1,000 per cycle. Cetrotide, which prevents premature ovulation, dropped from $316 to $22.50. Ovidrel, used to trigger ovulation, decreased from $251 to $84.
TrumpRx allows patients to bypass insurance formulary restrictions and access negotiated prices directly. For families already paying for fertility medications without insurance coverage, the approach offers a more straightforward purchasing method than facing the traditional system.
Success rates for IVF vary significantly based on age, diagnosis and other factors, often requiring patients to undergo multiple cycles. Each cycle involves additional invasive procedures and expensive medications, making cumulative costs a critical barrier to care.
